TY - JOUR
T1 - Myeloid-derived suppressor cells in cancer patients
T2 - A clinical perspective
AU - Montero, Alberto J.
AU - Diaz-Montero, Claudia Marcela
AU - Kyriakopoulos, Christos E.
AU - Bronte, Vincenzo
AU - Mandruzzato, Susanna
PY - 2012/2
Y1 - 2012/2
N2 - Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.
AB - Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.
KW - myeloid cells
KW - myeloid-derived suppressor cells
KW - suppression
UR - http://www.scopus.com/inward/record.url?scp=84856899903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856899903&partnerID=8YFLogxK
U2 - 10.1097/CJI.0b013e318242169f
DO - 10.1097/CJI.0b013e318242169f
M3 - Article
C2 - 22306898
AN - SCOPUS:84856899903
VL - 35
SP - 107
EP - 115
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1053-8550
IS - 2
ER -